
CSL
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after tapping Amazon's c...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare product...
Latest News
7 days ago · globenewswire.com
BROAD ARROW'S ZÜRICH AUCTION CONCLUDES A REMARKABLE 2026 AUCTION CALENDARBroad Arrow closes a spectacular 2026 auction calendar with second Zürich Auction at the historic Dolder Grand Hotel on 7 November | Highlights include a rare Bianco Fuji Ferrari LaFerrari that sold for CHF 5'856'250, and the Geneva Motor Show 2012 Bugatti Veyron 16.4 Grand Sport Vitesse that achieved CHF 2'368'750 | Former BMW Sauber F1 driver, Nick Heidfeld drove his rare 2023 BMW 3.0 CSL to the auction where it sold for CHF 906'250 | 2020 Aston Martin DB5 Goldfinger Edition, complete with replica gadgets sold for CHF 765,625 | Complete results from Broad Arrow's Zürich Auction along with 2027 auction information now available at broadarrowauctions.com Broad Arrow closes a spectacular 2026 auction calendar with second Zürich Auction at the historic Dolder Grand Hotel on 7 November | Highlights include a rare Bianco Fuji Ferrari LaFerrari that sold for CHF 5'856'250, and the Geneva Motor Show 2012 Bugatti Veyron 16.4 Grand Sport Vitesse that achieved CHF 2'368'750 | Former BMW Sauber F1 driver, Nick Heidfeld drove his rare 2023 BMW 3.0 CSL to the auction where it sold for CHF 906'250 | 2020 Aston Martin DB5 Goldfinger Edition, complete with replica gadgets sold for CHF 765,625 | Complete results from Broad Arrow's Zürich Auction along with 2027 auction information now available at broadarrowauctions.com
21 days ago · seekingalpha.com
CSL Limited (CSLLY) Shareholder/Analyst Call TranscriptCSL Limited (CSLLY) Shareholder/Analyst Call Transcript
27 days ago · prnewswire.com
CSL appoints Deborah Waterhouse as CEO & Managing DirectorMELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 February 2027. The appointment was made following an extensive global search process conducted by CSL's Board of Directors.
27 days ago · reuters.com
Australia's CSL appoints Deborah Waterhouse as CEOOct 21 (Reuters) - Australia's CSL (CSL.
1 month ago · zacks.com
HRMY vs. CSLLY: Which Stock Is the Better Value Option?Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
1 month ago · prnewswire.com
CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras/PRNewswire/ -- CSL y Alentis Therapeutics han anunciado hoy la firma de un acuerdo de colaboración global exclusiva para desarrollar y promocionar
1 month ago · proactiveinvestors.com
CSL strikes US$1.6 billion licensing deal for rare disease drugCSL Limited (ASX:CSL) has secured an exclusive licensing agreement with Swiss biotechnology company Alentis Therapeutics to develop and commercialise lixudebart, an experimental treatment targeting rare kidney and liver diseases. The deal gives CSL rights to advance the drug, which is currently in Phase 2 trials for ANCA-associated vasculitis, a rare autoimmune disease that can cause severe kidney damage.
1 month ago · reuters.com
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm AlentisAustralia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development funding.
1 month ago · prnewswire.com
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseasesAlentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases. Lixudebart is currently being evaluated in the ongoing Phase 2 RENAL trial in patients with ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a rare and potentially life-threatening autoimmune disease that can cause irreversible kidney damage and end-stage renal disease.
2 months ago · reuters.com
Australia's CSL taps Amazon's cloud unit to boost research pipelineAustralian biotechnology firm CSL said on Tuesday it is collaborating with Amazon's cloud arm to harness AI and cloud technology across its research and clinical development pipeline.
Add to Watchlist
Select watchlists to add or remove CSLLY